Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Overview

Journal Cancer Discov

Specialty Oncology

Date 2023 Oct 20

PMID 37861461

Authors

William K Kelly

Daniel C Danila

Chia-Chi Lin

Jae-Lyun Lee

Nobuaki Matsubara

Patrick J Ward

Andrew J Armstrong

David Pook

Miso Kim

Tanya B Dorff

Stefanie Fischer

Yung-Chang Lin

Lisa G Horvath

Christopher Sumey

Zhao Yang

Gabor Jurida

Kristen M Smith

Jamie N Connarn

Hweixian L Penny

Julia Stieglmaier

Leonard J Appleman

Affiliations

Soon will be listed here.

Abstract

Significance: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Nolan-Stevaux et al., p. 90. This article is featured in Selected Articles from This Issue, p. 5.

Citing Articles

Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles.

Castagnino P, Haas D, Musante L, Tancler N, Tran B, Kean R Cancer Biol Ther. 2025; 26(1):2455722.

PMID: 39863992 PMC: 11776462. DOI: 10.1080/15384047.2025.2455722.

Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies.

Khorasanchi A, Jatwani K, Meng L, Collier K, Sundi D, Dason S Cancers (Basel). 2025; 16(24).

PMID: 39766027 PMC: 11674059. DOI: 10.3390/cancers16244127.

Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies.

Nolan-Stevaux O, Smith R Front Immunol. 2024; 15:1490911.

PMID: 39606234 PMC: 11599190. DOI: 10.3389/fimmu.2024.1490911.

A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer.

Phung S, Zorko N, Soignier Y, Waller R, Shackelford M, Walker J Cancer Immunol Res. 2024; 13(2):258-272.

PMID: 39545924 PMC: 11790377. DOI: 10.1158/2326-6066.CIR-24-0273.

A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies.

Moore G, Zeng V, Diaz J, Bonzon C, Avery K, Rashid R Mol Cancer Ther. 2024; 24(3):331-344.

PMID: 39301613 PMC: 11876962. DOI: 10.1158/1535-7163.MCT-24-0327.

References

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T . AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov. 2023; 14(1):90-103. DOI: 10.1158/2159-8290.CD-23-0984. View

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

Wadosky K, Koochekpour S . Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016; 7(39):64447-64470. PMC: 5325456. DOI: 10.18632/oncotarget.10901. View

Zhou S, Liu M, Ren F, Meng X, Yu J . The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021; 9(1):38. PMC: 8157659. DOI: 10.1186/s40364-021-00294-9. View

Nathan P, Hassel J, Rutkowski P, Baurain J, Butler M, Schlaak M . Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021; 385(13):1196-1206. DOI: 10.1056/NEJMoa2103485. View

Sorrentino C, Di Carlo E . Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges. Cancers (Basel). 2023; 15(11). PMC: 10251915. DOI: 10.3390/cancers15112885. View

Antonarakis E, Park S, Goh J, Shin S, Lee J, Mehra N . Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023; 41(22):3839-3850. PMC: 10419579. DOI: 10.1200/JCO.23.00233. View

Powles T, Yuen K, Gillessen S, Kadel 3rd E, Rathkopf D, Matsubara N . Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022; 28(1):144-153. PMC: 9406237. DOI: 10.1038/s41591-021-01600-6. View

10.

Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl U . Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. Res Rep Urol. 2022; 14:339-350. PMC: 9529226. DOI: 10.2147/RRU.S360444. View

11.

Neuenschwander B, Branson M, Gsponer T . Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008; 27(13):2420-39. DOI: 10.1002/sim.3230. View

12.

Lim E, Schweizer M, Chi K, Aggarwal R, Agarwal N, Gulley J . Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023; 21(3):366-375. PMC: 10219845. DOI: 10.1016/j.clgc.2023.02.010. View

13.

Xu M, Evans L, Bizzaro C, Quaglia F, Verrillo C, Li L . STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Cancers (Basel). 2022; 14(16). PMC: 9406800. DOI: 10.3390/cancers14164034. View

14.

Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N . Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023; 185:178-215. DOI: 10.1016/j.ejca.2023.02.018. View

15.

Coiffier B, Altman A, Pui C, Younes A, Cairo M . Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26(16):2767-78. DOI: 10.1200/JCO.2007.15.0177. View

16.

Ravi G, Costa L . Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2022; 98 Suppl 2:S13-S21. DOI: 10.1002/ajh.26628. View

17.

Atallah-Yunes S, Robertson M, Dave U, Ghione P, Perna F . Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era. Front Immunol. 2022; 13:901365. PMC: 9198279. DOI: 10.3389/fimmu.2022.901365. View

18.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

19.

Danila D, Szmulewitz R, Vaishampayan U, Higano C, Baron A, Gilbert H . Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019; 37(36):3518-3527. PMC: 7351321. DOI: 10.1200/JCO.19.00646. View

20.

Ball K, Dovedi S, Vajjah P, Phipps A . Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs. 2023; 15(1):2181016. PMC: 9980545. DOI: 10.1080/19420862.2023.2181016. View